Literature DB >> 19287963

Interaction between survivin and aurora-B kinase plays an important role in survivin-mediated up-regulation of human telomerase reverse transcriptase expression.

Momoko Furuya1, Naoki Tsuji, Daisuke Kobayashi, Naoki Watanabe.   

Abstract

Survivin, a member of the apoptosis inhibitor family, shows increased expression in human cancers of various origins. It has been demonstrated that survivin inhibits apoptosis via caspase inhibition and promotes mitosis via aurora-B kinase activation. We recently reported that survivin enhances the expression of human telomerase reverse transcriptase (hTERT), a major determinant of telomerase activity in colon cancer cells. Survivin up-regulates hTERT expression by promoting the expression of specificity protein-1 (Sp1)- and c-Myc-mediated gene transcription via enhancing the phosphorylation of these transcriptional factors. However, the mechanism by which survivin regulates the phosphorylation of Sp1 and c-Myc is not well defined. In the present study, we hypothesized that survivin promotes the phosphorylation of Sp1 and c-Myc by activating aurora-B kinase. Inhibition of this enzyme by introducing small inhibitory RNA attenuated the phosphorylation of Sp1 and c-Myc and resulted in the abolition of the survivin effect on hTERT expression. In addition, blocking survivin phosphorylation at a threonine residue by inhibiting cyclin-dependent kinase 1 caused the dissociation of aurora-B kinase from survivin and attenuated the up-regulation of hTERT expression by survivin. Taken together, these results suggest that the interaction between survivin and aurora-B kinase may be essential for survivin to increase hTERT expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19287963     DOI: 10.3892/ijo_00000232

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.

Authors:  Alexander Hoellein; Mohammad Fallahi; Stephanie Schoeffmann; Sabine Steidle; Franz X Schaub; Martina Rudelius; Iina Laitinen; Lisa Nilsson; Andrei Goga; Christian Peschel; Jonas A Nilsson; John L Cleveland; Ulrich Keller
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

2.  Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.

Authors:  Jürgen den Hollander; Sara Rimpi; Joanne R Doherty; Martina Rudelius; Andreas Buck; Alexander Hoellein; Marcus Kremer; Nikolas Graf; Markus Scheerer; Mark A Hall; Andrei Goga; Nikolas von Bubnoff; Justus Duyster; Christian Peschel; John L Cleveland; Jonas A Nilsson; Ulrich Keller
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

3.  Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy.

Authors:  Thomas W Owens; Andrew P Gilmore; Charles H Streuli; Fiona M Foster
Journal:  J Carcinog Mutagen       Date:  2013-05-27

Review 4.  Telomerase as a useful target in cancer fighting-the breast cancer case.

Authors:  Hanna Holysz; Natalia Lipinska; Anna Paszel-Jaworska; Blazej Rubis
Journal:  Tumour Biol       Date:  2013-04-05

5.  The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro.

Authors:  Riccardo Adamo; Alessandro Comandini; Angelo Aquino; Laura Bonmassar; Loredana Guglielmi; Enzo Bonmassar; Ornella Franzese
Journal:  J Exp Clin Cancer Res       Date:  2013-06-08

Review 6.  The twisted survivin connection to angiogenesis.

Authors:  C Sanhueza; S Wehinger; J Castillo Bennett; M Valenzuela; G I Owen; A F G Quest
Journal:  Mol Cancer       Date:  2015-11-19       Impact factor: 27.401

7.  Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.

Authors:  Anna Capasso; Todd M Pitts; Peter J Klauck; Stacey M Bagby; Lindsey Westbrook; Jeffrey Kaplan; Milad Soleimani; Anna Spreafico; John J Tentler; Jennifer R Diamond; John J Arcaroli; Wells A Messersmith; Sue G Eckhardt; Stephen Leong
Journal:  Anticancer Drugs       Date:  2018-10       Impact factor: 2.248

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.